AbbVie Cited in Long-Term Dividend Feature; Payout Growth Streak at 54 Years
What happened
AbbVie (ABBV) was highlighted in a Motley Fool feature identifying five dividend stocks seen as candidates for long-term income portfolios. AbbVie has extended its dividend growth streak to 54 consecutive years when including its Abbott Laboratories lineage. The company currently yields approximately 3.4%. AbbVie's immunology and oncology pipeline, including Skyrizi and Rinvoq, has been cited as supporting payout sustainability as Humira biosimilar headwinds continue to moderate.
The QL Read
QuantLogix carries ABBV at a composite 42/100 (Sell) against a market backdrop where breadth is marginally positive at 52.5% advancing — a near-neutral tape that does little to offset the engine's bearish factor tilt on this name.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.